Matches in Nanopublications for { ?s ?p "[Therefore, we propose that CTA-specific immunotherapy for AML should preferentially target PRAME and/or should be combined with the application of demethylating agents opening the perspective for alternative targets like CTA SSX-2.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 11 of
11
with 100 items per page.
- NP298558.RAsvfyQgHJgDaq7Hxg7iP7Nn1kalvvfS54PB6F8mqq6u8130_assertion description "[Therefore, we propose that CTA-specific immunotherapy for AML should preferentially target PRAME and/or should be combined with the application of demethylating agents opening the perspective for alternative targets like CTA SSX-2.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP298558.RAsvfyQgHJgDaq7Hxg7iP7Nn1kalvvfS54PB6F8mqq6u8130_provenance.
- NP393954.RAvMXisqz2MkoANIVJGYklNY57KD_laBbDK7Ef6-BuW18130_assertion description "[Therefore, we propose that CTA-specific immunotherapy for AML should preferentially target PRAME and/or should be combined with the application of demethylating agents opening the perspective for alternative targets like CTA SSX-2.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP393954.RAvMXisqz2MkoANIVJGYklNY57KD_laBbDK7Ef6-BuW18130_provenance.
- NP874527.RA94dNxC3nPOtYEzffghFJeDXIcmXPNE9IZQqvmAB2Jao130_assertion description "[Therefore, we propose that CTA-specific immunotherapy for AML should preferentially target PRAME and/or should be combined with the application of demethylating agents opening the perspective for alternative targets like CTA SSX-2.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP874527.RA94dNxC3nPOtYEzffghFJeDXIcmXPNE9IZQqvmAB2Jao130_provenance.
- NP1009226.RA6eMJH8WZUno8DSWVwRqcT_U5tK2Bk73boIPL_GUp-DU130_assertion description "[Therefore, we propose that CTA-specific immunotherapy for AML should preferentially target PRAME and/or should be combined with the application of demethylating agents opening the perspective for alternative targets like CTA SSX-2.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1009226.RA6eMJH8WZUno8DSWVwRqcT_U5tK2Bk73boIPL_GUp-DU130_provenance.
- NP714786.RAMvJxfTHSZThlteFwBoF8-lYjTwAbM_DUANYqRobSHiQ130_assertion description "[Therefore, we propose that CTA-specific immunotherapy for AML should preferentially target PRAME and/or should be combined with the application of demethylating agents opening the perspective for alternative targets like CTA SSX-2.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP714786.RAMvJxfTHSZThlteFwBoF8-lYjTwAbM_DUANYqRobSHiQ130_provenance.
- NP921891.RAUR4-hYgM17uXFrZqdnqDZ8stvmMqYj7Ah3g18KtxgwE130_assertion description "[Therefore, we propose that CTA-specific immunotherapy for AML should preferentially target PRAME and/or should be combined with the application of demethylating agents opening the perspective for alternative targets like CTA SSX-2.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP921891.RAUR4-hYgM17uXFrZqdnqDZ8stvmMqYj7Ah3g18KtxgwE130_provenance.
- assertion description "[Therefore, we propose that CTA-specific immunotherapy for AML should preferentially target PRAME and/or should be combined with the application of demethylating agents opening the perspective for alternative targets like CTA SSX-2.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Therefore, we propose that CTA-specific immunotherapy for AML should preferentially target PRAME and/or should be combined with the application of demethylating agents opening the perspective for alternative targets like CTA SSX-2.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP921892.RAgvaMZQ86e1S6PTtzyiMOVjcdSBDrDbMCDUWwjQCoqnc130_assertion description "[Therefore, we propose that CTA-specific immunotherapy for AML should preferentially target PRAME and/or should be combined with the application of demethylating agents opening the perspective for alternative targets like CTA SSX-2.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP921892.RAgvaMZQ86e1S6PTtzyiMOVjcdSBDrDbMCDUWwjQCoqnc130_provenance.
- NP921893.RAETirq_6MP1eO3rhPeFPP1Kkqfb9gYnADWTO12UQecY0130_assertion description "[Therefore, we propose that CTA-specific immunotherapy for AML should preferentially target PRAME and/or should be combined with the application of demethylating agents opening the perspective for alternative targets like CTA SSX-2.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP921893.RAETirq_6MP1eO3rhPeFPP1Kkqfb9gYnADWTO12UQecY0130_provenance.
- assertion description "[Therefore, we propose that CTA-specific immunotherapy for AML should preferentially target PRAME and/or should be combined with the application of demethylating agents opening the perspective for alternative targets like CTA SSX-2.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.